EGFR and colorectal carcinoma: No significant differences in percentages of EGFR, HER2, and HER3-positive cells (p ≥ 0.652) and ΔMFI of receptor-positive cells (p ≥ 0.695) were observed between cetuximab-sensitive, intrinsically-resistant, and acquired cetuximab-resistant CRC cell lines.